Conversations at the crossroads of science and capital.
Welcome to Clinical Capital Conversations, a podcast and editorial platform hosted by Dr. Peter M. Kovacs, a clinical research pioneer turned global investor.
At the intersection of cutting-edge science and strategic investment, we explore what it really takes to turn medical innovation into scalable impact.
Each episode features unfiltered conversations with:
Clinical research leaders are redefining how trials are run
Biotech and medtech founders building from scratch
Venture capitalists are funding the next generation of health innovation
Policymakers, regulators, and thought leaders shaping the future of medicine
Peter brings his first-hand experience, from founding one of the Worlds most agile clinical trial networks to investing in disruptive health tech startups across Asia and Europe.
This is not another hype podcast. It’s a behind-the-scenes look at how decisions are made, systems are built, and real therapies reach real patients.
Whether you’re a startup founder, scientist, investor, or healthcare strategist, CCC is your front-row seat to the people and ideas moving life sciences forward.
Join Clinical Capital Conversations and be part of the dialogue at the crossroads of science and capital. Get insights, unfiltered stories, and updates on how medical innovation turns into real-world impact, straight to your inbox.
Building the Central European Venture Engine: From Founders to Scalable Companies
Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer of Uniprisma about founder psychology, scaling discipline, and why the next wave of innovation will come from execution, not hype.
From Pain to Purpose: Scaling Femtech with Precision and Purpose
A powerful conversation with YON E Health founders on transforming trauma into innovation. Peter M. Kovacs explores how Femtech is closing clinical data gaps, redefining investment, and scaling inclusive health technology.
AI in Europe: Building Bridges Between Policy, Business, and Healthcare
AI in Europe requires both ethics and competitiveness. In this episode, Peter M. Kovacs, Pavlina Walter, and Jan Kavalírek explore AI regulation, EU bureaucracy, and the balance between trust, safety, and global competition.
Access to Patients - The Hardest Part of Clinical Research
Patient access is the biggest bottleneck in clinical trials. This article explores why recruitment is so difficult, how databases, referrals, and digital outreach help, and why solving this issue is critical to delivering life-changing treatments faster.
Who We Are: PMK Group and Our Mission in Biotech
PMK Group reduces biotech risk by combining capital with clinical expertise. Dr. Peter M. Kovacs explains how operational involvement lowers trial failures and accelerates medical innovation.
AI and Healthcare Innovation with Lukas Benzel, Pavlina Walterand Peter M. Kovacs
Prague podcast on AI and healthcare with Peter M. Kovacs, Pavlina Walter, and Lukas Benzel. From hospital adoption to prevention, clinical trials, EU strategy, and lessons from Singapore. Practical playbooks for investors, founders, and operators.
From Budapest to Singapore - A Life-Changing Decision
From Budapest to Singapore, Dr. Peter M. Kovacs shares his bold move to Asia, explains why Singapore became his global hub, and discusses its implications for healthcare, biotech, and investment.
Clinical Research Doesn’t Need More Money, It Needs Better Execution
Clinical research doesn’t need more funding, it needs better execution. Discover a proven operational model that accelerates milestones, improves data quality, and reduces capital waste by 30–50%, offering a strategic edge for institutional co-investors.
A Systematic Approach for De-Risking Biotech and MedTech Investments
Unlock consistent risk-adjusted returns in biotech & MedTech. Learn our systematic approach to de-risking investments by preventing technical execution failures. Our proven methodology, built on 23+ years of experience, reduces capital needs by 30-50% and accelerates milestones, offering a unique opportunity for institutional co-investors.